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John A. Kellum* and Raghavan MuruganAcute kidney injury (AKI) is a serious medical condition
estimated to affect more than ten million people around
the world annually [1]. AKI results in a 1.7- to 6.9-fold
increased risk of hospital mortality, and risk-adjusted
rates of AKI and mortality appear similar across the
world [2]. Patients who develop AKI also have worse
kidney function at hospital discharge and thus far more
risk for chronic kidney disease [2]. However, these risks
are most clearly apparent for patients with very severe
AKI, such as those who receive renal replacement therapy
(RRT). Milder forms of AKI are less clearly associated
with adverse outcomes and thus it is unclear whether mild
AKI is in the causal pathway for morbidity and mortality.
For example, in a large international study of patients
cared for in the intensive care unit (ICU), stage 2 or 3
AKIs were strongly associated with mortality even after
risk adjustment, whereas for patients incurring only
stage 1 AKI the association was attenuated and no
longer significant (odds ratio 1.68, 95 % confidence
interval (CI) 0.89–3.17; P = 0.11) [2].
For purposes of this review, we define “non-severe
AKI” as AKI that is not managed by RRT. We acknow-
ledge that this is an imperfect definition because the
decision to commence RRT is often a difficult one and
there exists considerable heterogeneity across centers
and among physicians, even experts. Thus, the same
patient could be counted as non-severe if cared for by
one clinician but severe if cared for by another. Although
differences exist at the individual patient-provider level,
rates of RRT for critically ill patients with AKI in general,
though increasing, are relatively consistent around the
world [2, 3]. For example, a decade ago, Uchino and
colleagues found that in 23 countries on four continents
4.2 % of patients admitted to the ICU received RRT for
AKI and this rate was not different between world regions
(95 % CI 4.0–4.4 %) [3]. Similarly, Hoste and colleagues* Correspondence: kellumja@ccm.upmc.edu
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13.5 % of all patients admitted to the ICU (excluding
patients with end-stage renal disease) received RRT
for AKI; again, the range was rather narrow (95 % CI
12.0–15.1 %) [2]. Approximately 25 % of critically ill
patients with AKI receive RRT; this article is about
the remaining 75 %.Acute kidney injury in less critically ill patients
A problem complementary to non-severe AKI is “AKI in
non-severely ill patients”. One third of patients hospital-
ized for community-acquired pneumonia develop AKI
and have significantly lower 1-year survival compared
with those who do not develop AKI [4]. Furthermore,
AKI is common even in patients outside the ICU or with
non-severe pneumonia [4]. For example, we showed
that AKI occurred in 25 % of patients admitted with
community-acquired pneumonia to a hospital bed out-
side the ICU [4]. Despite the low overall acuity, patients
developing AKI had a more than fourfold increased risk
of death in-hospital (1.2 % versus 5.1 %) and a nearly two-
fold increase at 1 year (19.7 % versus 34.2 %; P < 0.001).
Even within the ICU, patients with lower severity, defined
by absence of circulatory or respiratory failure, had just as
great an absolute risk (and higher relative risk) of death
associated with AKI [5]. “Low-severity” patients may be at
greater relative risk from AKI because of the perception
that these patients are not severely ill. Similar results were
observed by Joannidis and colleagues, who reported that
AKI contributed more to mortality in patients with lower
baseline severity of illness [6]. Such patients are usually
judged to be at lower risk for developing AKI and are less
likely to receive recommended interventions for high-risk
patients such as avoidance of unnecessary nephrotoxic
drugs and radiocontrast, close monitoring of serum cre-
atinine and urine output, and assessment of fluid status
[7]. The National Health Service in the UK has systematic-
ally assessed the care and outcomes for patients with AKI
and found that inadequate risk assessment is common
and is associated with delays in treatment, and investigatorshis article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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altogether [8].
Similar limitations can be seen in studies evaluating
novel biomarkers for AKI that have specifically focused
on high-risk patients [9]. Ironically, although many more
events will be seen in high-risk patients, the relative
impact of AKI on survival is actually greatest in low-risk
patients [5]. For patients without other organ failures, it
may be easier, by virtue of their lower clinical complex-
ity, to prevent AKI from developing in the first place.
This leads to the supposition that efforts to curtail AKI
in critically ill patients might be more effective if applied
to low-risk patients or at least that low-risk patients
should not be excluded.Limitations of current staging
In addition to the imprecision engendered by classifying
AKI as “non-severe” by virtue of not being treated with
RRT, the underlying AKI staging system first proposed
by the Acute Dialysis Quality Initiative (ADQI) [10] and
codified by the Kidney Disease Improving Global Out-
comes (KDIGO) AKI workgroup [7] has important limita-
tions. First, although urine output and serum creatinine
are both measures of renal function and their changes
do track, to some extent, with the severity of injury, the
current staging system does not consider the effects of
abnormalities in both domains compared with just one.
For example, as shown in Table 1, the combination of
oliguria and increases in serum creatinine portends far
worse outcomes than either abnormality itself [11].Table 1 Relationship between urine output and serum creatinine cr
KDIGO stage Urine output only
No AKI















AKI acute kidney injury, KDIGO Kidney Disease Improving Global Outcomes, RRT renThus, a patient with “stage 1” AKI by both serum cre-
atinine and urine output criteria actually has the same
risk of death by hospital discharge (11.3 %) than a pa-
tient with stage 2 criteria by serum creatinine alone (no
oliguria) and a greater risk compared with stage 2 by
urine output criteria alone (7.9 %). Similarly, adding
oliguria (stage 1 criteria) to stage 3 creatinine criteria
increases risk of death by more than threefold and risk
for RRT by nearly fivefold. Adding creatinine (stage 1)
to stage 3 urine output criteria has a twofold increased
risk of death with a 10-fold increased risk for RRT.
These short-term outcomes were mirrored by 1-year
outcomes [11].
Another limitation to the KDIGO staging system is
that duration of AKI is not considered [12]. Although
even short episodes of AKI are associated with adverse
outcomes [13], persistent AKI is clearly worse [11, 13, 14].
AKI may also appear less severe because serum creatinine
is affected by disease severity. Creatinine is formed from
non-enzymatic dehydration of creatine in the liver, and
98 % of the creatine pool is in muscle [15]. Thus, condi-
tions which increase muscle breakdown may increase cre-
atinine generation whereas conditions that reduce muscle
mass, muscle perfusion, and liver function may decrease
creatinine generation. Fluid overload may result in artifi-
cial lowering of the serum creatinine level and misclassifi-
cation of AKI staging [16]. Finally, we should not forget
that in patients with normal baseline renal function a
clinical AKI event already represents substantial loss of
kidney function. This is because the kidney has significant
renal functional reserve such that more than 50 % of renaliteria and clinical outcomes
Stage 1 Stage 2 Stage 3 Total
3158 5421 440 17,198
5.3 % 7.9 % 17.7 % 5.9 %
0.0 % 0.1 % 1.1 % 0.1 %
1262 3485 842 7478
11.3 % 13.0 % 32.1 % 13.6 %
0.7 % 0.6 % 10.9 % 1.7 %
476 1533 831 3458
23.9 % 21.5 % 44.2 % 25.5 %
1.3 % 1.7 % 21.7 % 6.3 %
321 1,019 2,200 3911
38.6 % 28.0 % 51.1 % 40.3 %
17.8 % 14.2 % 55.3 % 36.6 %
5217 11,458 4313 32,045
10.5 % 13.0 % 42.6 % 14.0 %
1.4 % 1.7 % 34.6 % 5.6 %
al replacement therapy. Adapted from Kellum et al. [11] (with permission)
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increases [17]. AKI biomarkers may be useful in closing
this diagnostic gap. Some markers appear to be sensitive
to “subclinical AKI” [18], whereas other markers appear to
predict long-term outcomes, such as death or dialysis,
only when patients develop clinical AKI [19].
For example, tissue inhibitor metalloproteinase-2
(TIMP-2) and insulin-like growth factor-binding protein-7
(IGFBP7) have been associated with 9-month incidence of
a composite end point of all-cause mortality or the need
for RRT in critically ill adults [19]. In univariate analysis,
[TIMP-2]•[IGFBP7] of more than 2.0 was associated
with increased risk of the composite end point (hazard
ratio (HR) 2.11, 95 % CI 1.37–3.23; P < 0.001). In a
multivariate analysis adjusted for the clinical model,
[TIMP-2]•[IGFBP7] of more than 0.3 was associated
with death or RRT only in subjects who developed AKI
(compared with levels of not more than 0.3: HR 1.44,
95 % CI 1.00–2.06 for levels of more than 0.3 to 2.0,
P = 0.05; and HR 2.16, 95 % CI 1.32–3.53 for levels of
more than 2.0, P = 0.002) [19].
Pathophysiology of non-severe acute kidney
injury
If the associations between non-severe AKI and out-
comes like mortality are causal, what would be the
mechanisms? Even without being severe enough to war-
rant RRT, AKI affects multiple body systems. Three
particularly important areas appear to be immune dys-
function, fluid overload, and adverse drug events (ADEs).
Mehta and colleagues [20] reported that in 40 % of ICU
patients with sepsis and AKI, sepsis occurred after
AKI. This may in fact be an underestimate since they
used serum creatinine—well known to be a delayed
criterion—to diagnose AKI. Experimentally, we showed
that AKI due to folic acid nephrotoxicity or myohemoglo-
binuria causes impaired neutrophil function apparent
in vivo and in vitro [21]. Specifically, mice with AKI and
pneumonia had worse bacterial invasion and lung injury
than pneumonia alone, and neutrophils isolated from
mice with AKI had impaired transmigration and F-actin
polymerization in vitro. Together with an emerging litera-
ture on the various pathophysiologic effects of AKI [22],
these results establish a scientific foundation for the effect
of AKI on the immune system and on the risk for sepsis.
They are also reminiscent of more well-established litera-
ture on the effects of chronic kidney disease on innate
immunity.
Fluid overload has emerged as a major concern for
clinically ill patients [23–25]. Fluid overload may lead to
tissue edema that may affect virtually every organ system
[26]. Cerebral edema may cause cognitive dysfunction.
Pulmonary edema may lead to impaired gas exchange and
prolong the need for mechanical ventilation. Myocardialedema leads to cardiac dysrhythmias and may impair
myocardial performance. Edema of the liver, kidneys, and
intestines can decrease organ function, and tissue edema
can impair wound healing and predispose to skin break-
down. Ironically, fluid overload may actually be a larger
problem for patients “not severe enough” for treatment
with RRT since RRT is an effective way to manage fluid
balance.
Finally, ADEs are common in the ICU, and AKI is a
significant risk factor. Indeed, AKI shares a bidirectional
relationship with ADEs. Drugs may complicate the
course of as many as a quarter of patients with AKI in
the ICU and up to 72 % in hospitalized patients [2, 3, 27].
Conversely, 770,000 hospitalized patients per year are
injured or die because of ADEs [28], and AKI has been
identified as a strong risk factor for ADEs [29]. A common
cause of ADEs is the inappropriate prescribing of drugs,
specifically in patients with AKI [30]. The majority of
drugs are excreted by the kidney; so once AKI occurs, it is
important to be vigilant to manage drug dosing and pre-
vent resultant ADEs. Unfortunately, this is often not the
case and drug reconciliation and dosing adjustment are
often relegated to lower priority when the complexities of
critical illness compete for clinician attention.
Conclusions
Even when AKI is “less severe” and does not require
RRT, it still may be in the causal pathway for morbidity
and mortality in critically ill patients. Effects of renal
dysfunction on immune function, fluid balance, and drug
clearance may result in a myriad of complications,
prolonging hospitalization and increasing risk of death.
Recent advances in the understanding of AKI epidemi-
ology, biomarkers, and electronic surveillance have offered
potential solutions to the complex problems of identifying
and managing AKI, but more is needed. Clinicians need
to be aware of the risks and remain vigilant to prevent
complications. Evolution in disease management from
severe to “less severe” is familiar to us all. The emergence
of non-ST segment myocardial infarction and “precancer-
ous syndromes” are both examples of evolving patho-
nomenclature as the epidemiology and pathobiology of
diseases like coronary artery disease and cancer advance.
We should expect the same as we move from acute renal
failure to AKI.
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